superior industrial supply co. blue logo
0

Blog Layout

Poppy

Foreign sources of opium Poppy are responsible for the entire supply of heroin consumed in the U.S. Efforts to reduce domestic heroin availability face significant problems. Unlike cocaine, which is concentrated in South America, opium production occurs in three source regions—Southeast Asia, Southwest Asia, and Latin America- creating a worldwide problem. While an undetermined amount of the opium is consumed in the producing regions, a significant amount of the drug is converted to heroin and sent to Europe and North America.


Historically, most of the world’s illicit opium for heroin has been grown in the Golden Triangle of Southeast Asia. However, Latin America has emerged, in recent years, as the primary supplier of heroin to the United States. Colombian and Mexican heroin comprises 60 and 24 percent respectively of the heroin seized today in the United States. Low-level opium-poppy cultivation in Venezuela and even more limited growing in Peru currently produce only marginal amounts of heroin but could become the foundation for an expanding opium and heroin industry beyond Colombia. Opium-poppy cultivation in Venezuela is limited to the mountains opposite Colombia’s growing area and appears to be a spillover from cultivation on the Colombian side of the border. Reports indicate that opium poppy cultivation in Peru over the last several years is nearly negligible.


With long-established trafficking and distribution networks and exclusive markets for black tar and brown powder heroin, Mexico’s hold on the U.S. heroin market in the West seems secure. Mexico grows only about two percent of the world’s illicit opium, but virtually the entire crop is converted into heroin for the U.S. market. Opium cultivation and production in Mexico have been relatively stable through most of the 1990s.

Source: ONDCP Fact Sheet: “Breaking Heroin Sources of Supply.”


The U.S. State Department annually estimates yields of opium poppy and other narcotic crops around the world. This is a difficult task because poppy is grown illegally under a variety of conditions and in many locations. To understand how opium poppy growth, development, and gum yield can be affected by weather variables such as temperature, plants were grown in controlled environments at temperatures ranging from nighttime lows of 7 degrees C to daytime highs of 28 degrees C. The optimum temperature for growth was between 16 and 20 degrees C.

Plants in optimum temperatures had more leaf area per unit of leaf tissue. These plants captured more light and grew faster than plants under the influence of higher or lower temperatures.


Development rate (time to flower) was practically the same for plants grown in temperatures of 17.5 degrees C or above, but time to flower was increased by 10% if plants were grown in 13.5 degrees C and by 50% if they were grown in an average temperature of 9.5 degrees C. The yield of gum, which is collected from the capsule, was positively correlated with capsule dry weight and capsule volume. Conditions that favored growth also favored yield. By understanding these responses to temperature, we can better predict the effect of weather conditions on flowering times, growth, and yield of opium poppy around the world. Improved models of poppy growth will improve the U.S. State Department yield estimates and give Congress better information for directing the War on Drugs.


Technical Abstract: The U.S. State Department annually estimates yields of opium poppy (Papaver somniferum L.) and other narcotic crops around the world. Field sampling is preferred. However, field sampling is expensive and can be dangerous, so other techniques are being sought. One method is to simulate crop performance using a computer model. To develop such a model, crop response to soil conditions, weather, and management practices must be understood. The first step in this process is to examine crop growth in controlled environments, keeping all environmental factors except one at optimum levels, and varying the one factor over a wide range. To study the effects of temperature on opium poppy, young seedlings were grown in controlled environment chambers in a 12 h photoperiod at a light intensity of 1000 micromol with day/night temperatures of 12/7 degrees C, 16/11 degrees C, 20/15 degrees C, 24/19 degrees C and 28/23 degrees C. Dry weights of plant parts and specific leaf area (SLA) were measured at various stages during plant development. The optimum mean temperature for poppy growth was between 16 and 20 degrees C. Development rate was reduced at lower temperatures but remained relatively constant over the 20/15, 24/19, and 28/23 degrees C treatments. SLA was sensitive to temperature, maximizing at 19.5 degrees C. Variation in SLA could explain some differences in relative growth rate and growth rate associated with temperature. Gum yield could be estimated from capsule dry weight or capsule volume using a linear regression model (r2 =0.71 and 0.75 respectively). Analyses of these data represent a first step in quantifying the effects of temperature on poppy growth, development, and gum yield.



Other Sources:

Heroin | National Institute on Drug Abuse (NIDA)
https://www.drugabuse.gov/drugs-abuse/heroin

Brief Description Heroin is an opioid drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian …

Urine Drug Testing for Chronic Pain Management
www.drugabuse.gov/sites/default/files/files/UrineDrugTesting.pdf

Urine Drug Testing for Chronic Pain Management. Introduction. … Opiates Morphine 300-2,000 Poppy seeds Rifampin Chlorpromazine Dextromethorphan 2-4 …

Drug-FreeFederal Register Codification


By Bob Hansen January 29, 2022
Zyprexa (Olanzapine) is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder. More information/images in the Prescription Drug Brochure. When you receive Zyprexa extended-release injection, the medication is usually released slowly into your blood over a period of time. However, when you receive olanzapine extended-release injection, there is a small chance that olanzapine may be released into your blood too quickly. If this happens, you may experience a serious problem called Post-injection Delirium Sedation Syndrome (PDSS). If you develop PDSS, you may experience dizziness, confusion, difficulty thinking clearly, anxiety, irritability, aggressive behavior, weakness, slurred speech, difficulty walking, muscle stiffness or shaking, seizures, drowsiness, and coma (loss of consciousness for a period of time). You are most likely to experience these symptoms during the first 3 hours after you receive the medication. You will receive Zyprexa extended-release injection in a hospital, clinic, or another medical facility where you can receive emergency medical treatment if it is needed. You will need to remain in the facility for at least 3 hours after you receive the medication. While you are in the clinic, the medical staff will watch you closely for signs of PDSS. When you are ready to leave the facility, you will need a responsible person to be with you, and you should not drive a car or operate machinery for the rest of the day. Get emergency medical help right away if you experience any symptoms of PDSS after you leave the facility. A program has been set up to help people receive Zyprexa extended-release injection safely. You will need to register and agree to the rules of this program before you receive olanzapine extended-release injection. Your doctor, the pharmacy that dispenses your medication, and the medical facility where you receive your medication will also need to register. Ask your doctor if you have any questions about this program. For people being treated with olanzapine extended-release injection or Zyprexa injection: Studies have shown that older adults with dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and that may cause changes in mood and personality) who take antipsychotics (medications for mental illness) such as olanzapine have an increased chance of death during treatment. Older adults with dementia may also have a greater chance of having a stroke or mini-stroke during treatment. Olanzapine injection and olanzapine extended-release injection are not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia. Talk to the doctor who prescribed this medication if you, a family member, or someone you care for has dementia and is being treated with olanzapine injection or olanzapine extended-release injection. For more information visit the FDA website: http://www.fda.gov/Drugs Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with olanzapine extended-release injection and each time you receive an injection. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide. extended-release injection, the medication is usually released slowly into your blood over a period of time. However, when you receive olanzapine extended-release injection, there is a small chance that olanzapine may be released into your blood too quickly. If this happens, you may experience a serious problem called Post-injection Delirium Sedation Syndrome (PDSS). If you develop PDSS, you may experience dizziness, confusion, difficulty thinking clearly, anxiety, irritability, aggressive behavior, weakness, slurred speech, difficulty walking, muscle stiffness or shaking, seizures, drowsiness, and coma (loss of consciousness for a period of time). You are most likely to experience these symptoms during the first 3 hours after you receive the medication. You will receive olanzapine extended-release injection in a hospital, clinic, or another medical facility where you can receive emergency medical treatment if it is needed. You will need to remain in the facility for at least 3 hours after you receive the medication. While you are in the clinic, the medical staff will watch you closely for signs of PDSS. When you are ready to leave the facility, you will need a responsible person to be with you, and you should not drive a car or operate machinery for the rest of the day. Get emergency medical help right away if you experience any symptoms of PDSS after you leave the facility. A program has been set up to help people receive olanzapine extended-release injection safely. You will need to register and agree to the rules of this program before you receive olanzapine extended-release injection. Your doctor, the pharmacy that dispenses your medication, and the medical facility where you receive your medication will also need to register. Ask your doctor if you have any questions about this program. For people being treated with olanzapine extended-release injection or olanzapine injection: Studies have shown that older adults with dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and that may cause changes in mood and personality) who take antipsychotics (medications for mental illness) such as olanzapine have an increased chance of death during treatment. Older adults with dementia may also have a greater chance of having a stroke or mini-stroke during treatment. Olanzapine injection and olanzapine extended-release injection are not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia. Talk to the doctor who prescribed this medication if you, a family member, or someone you care for has dementia and is being treated with olanzapine injection or olanzapine extended-release injection. For more information visit the FDA website: http://www.fda.gov/Drugs  Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with olanzapine extended-release injection and each time you receive an injection. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide.
By Bob Hansen January 29, 2022
Zoloft (Sertraline) is included in the class of drugs called selective serotonin reuptake inhibitors (SSRIs). This class of drugs is used to treat depression, anxiety, and other mood disorders.
By Bob Hansen January 29, 2022
Zanaflex (Tizanidine) is a short-acting muscle relaxer. Tizanidine is used to relieve the spasms and increased muscle tone caused by multiple sclerosis (MS, a disease in which the nerves do not function properly and patients may experience weakness, numbness, loss of muscle coordination and problems with vision, speech, and bladder control), stroke, or brain or spinal injury. Tizanidine is in a class of medications called skeletal muscle relaxants. It works by slowing action in the brain and nervous system to allow the muscles to relax. Tizanidine comes as a tablet and a capsule to take by mouth. It is usually taken consistently either always with or always without food two or three times a day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take tizanidine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Tizanidine capsules may be opened and sprinkled on soft foods such as applesauce. Talk to your doctor before opening the capsules because the effects of the medication, when used in this manner, may be different than when swallowing the capsule whole. The medication in the capsule is absorbed differently by the body than the medication in the tablet, so one product cannot be substituted for the other. Each time you have your prescription filled, look at the tablets or capsules in the bottle and make sure that you have received the right product. If you think you received the wrong medication, talk to your doctor or pharmacist right away. Your doctor will probably start you on a low dose of tizanidine and gradually increase your dose, depending on your response to this medication.  Do not stop taking tizanidine without talking to your doctor. If you suddenly stop taking tizanidine, your heart may beat faster and you may have increased blood pressure or tightness in your muscles. Your doctor will probably decrease your dose gradually.
More Posts
Share by: